Pax World Management LLC continued to hold its position in shares of Abbott Laboratories (NYSE:ABT) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 46,224 shares of the healthcare product maker’s stock at the end of the second quarter. Pax World Management LLC’s holdings in Abbott Laboratories were worth $2,247,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in ABT. State Street Corp boosted its holdings in Abbott Laboratories by 18.9% in the first quarter. State Street Corp now owns 80,499,469 shares of the healthcare product maker’s stock valued at $3,574,987,000 after acquiring an additional 12,806,535 shares during the last quarter. Boston Partners boosted its holdings in Abbott Laboratories by 5,663.7% in the first quarter. Boston Partners now owns 8,212,035 shares of the healthcare product maker’s stock valued at $364,696,000 after acquiring an additional 8,069,557 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Abbott Laboratories by 11.0% in the first quarter. Bank of New York Mellon Corp now owns 33,796,869 shares of the healthcare product maker’s stock valued at $1,500,920,000 after acquiring an additional 3,344,508 shares during the last quarter. Ameriprise Financial Inc. boosted its holdings in Abbott Laboratories by 33.8% in the first quarter. Ameriprise Financial Inc. now owns 8,823,399 shares of the healthcare product maker’s stock valued at $391,841,000 after acquiring an additional 2,231,316 shares during the last quarter. Finally, Swiss National Bank boosted its holdings in Abbott Laboratories by 45.3% in the first quarter. Swiss National Bank now owns 6,528,788 shares of the healthcare product maker’s stock valued at $289,943,000 after acquiring an additional 2,035,170 shares during the last quarter. 71.39% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Pax World Management LLC Maintains Holdings in Abbott Laboratories (ABT)” was first published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://www.watchlistnews.com/pax-world-management-llc-maintains-holdings-in-abbott-laboratories-abt/1681935.html.

Abbott Laboratories (ABT) opened at $55.47 on Monday. The company has a current ratio of 2.69, a quick ratio of 2.26 and a debt-to-equity ratio of 0.72. Abbott Laboratories has a 12-month low of $37.38 and a 12-month high of $56.69. The firm has a market capitalization of $96,551.14, a P/E ratio of 23.02, a PEG ratio of 2.08 and a beta of 1.06.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.01. Abbott Laboratories had a return on equity of 13.98% and a net margin of 8.37%. The company had revenue of $6.83 billion for the quarter, compared to analyst estimates of $6.72 billion. During the same period in the prior year, the firm earned $0.59 earnings per share. Abbott Laboratories’s revenue for the quarter was up 28.8% on a year-over-year basis. research analysts predict that Abbott Laboratories will post 2.5 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th will be given a dividend of $0.265 per share. This represents a $1.06 dividend on an annualized basis and a dividend yield of 1.91%. The ex-dividend date is Thursday, October 12th. Abbott Laboratories’s payout ratio is 83.47%.

Several brokerages recently commented on ABT. Barclays PLC upped their target price on Abbott Laboratories from $57.00 to $60.00 and gave the company an “overweight” rating in a report on Thursday, September 28th. Zacks Investment Research cut Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Tuesday, September 26th. Stifel Nicolaus upped their target price on Abbott Laboratories from $58.00 to $63.00 and gave the company a “buy” rating in a report on Thursday, October 19th. BMO Capital Markets reiterated a “hold” rating and issued a $53.00 target price on shares of Abbott Laboratories in a report on Monday, October 2nd. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $65.00 target price on shares of Abbott Laboratories in a report on Thursday, October 19th. Seven analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Abbott Laboratories currently has an average rating of “Buy” and an average target price of $56.81.

In other news, insider Stephen R. Fussell sold 196,550 shares of the company’s stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $49.50, for a total transaction of $9,729,225.00. Following the transaction, the insider now directly owns 221,488 shares of the company’s stock, valued at $10,963,656. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Daniel Gesua Sive Salvadori sold 96,603 shares of the company’s stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $56.21, for a total value of $5,430,054.63. Following the transaction, the executive vice president now directly owns 142,082 shares in the company, valued at $7,986,429.22. The disclosure for this sale can be found here. Insiders have sold 408,313 shares of company stock worth $21,205,356 over the last ninety days. 0.76% of the stock is owned by insiders.

Abbott Laboratories Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.